Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: Molecular consequences and rescue of defect

Drug Metabolism and Disposition

Volumn 38, Issue 2, 2010, Pages 332-340

  Marohnic, Christopher C ^a   Panda, Satya P ^a   McCammon, Karen ^a   Rueff, José ^b   Masters, Bettie Sue Siler ^a   Kranendonk, Michel ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 REDUCTASE; ETHOXYRESORUFIN DEETHYLASE; FLAVINE ADENINE NUCLEOTIDE; FLAVINE MONONUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ARTICLE; CATALYSIS; ELECTRON TRANSPORT; ENZYME ACTIVITY; ENZYME BINDING; ENZYME DEFICIENCY; ESCHERICHIA COLI; FLUORESCENCE; GENE MUTATION; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

AMINO ACID SUBSTITUTION; CARCINOGENS; CIRCULAR DICHROISM; CYTOCHROME P-450 CYP1A2; ESCHERICHIA COLI; FLAVIN MONONUCLEOTIDE; FLAVIN-ADENINE DINUCLEOTIDE; HUMANS; KINETICS; MEMBRANES; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; MUTATION; NADH, NADPH OXIDOREDUCTASES; NADPH-FERRIHEMOPROTEIN REDUCTASE; PLASMIDS; RECOMBINANT FUSION PROTEINS; SPECTROMETRY, FLUORESCENCE; SPECTROPHOTOMETRY;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 76149123185     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.030445     Document Type: Article

References (39)

1. Adachi M, Tachibana K, Asakura Y, Yamamoto T, Hanaki K, and Oka A (2004) Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley-Bixler syndrome. Am J Med Genet A 128:333-339.
2. Agrawal V, Huang N, and Miller WL (2008) Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet Genomics 18:569-576.
3. Aigrain L, Pompon D, Moréra S, and Truan G (2009) Structure of the open conformation of a functional chimeric NADPH cytochrome P450 reductase. EMBO Rep 10:742-747.
4. Antley R and Bixler D (1975) Trapezoidocephaly, midfacial hypoplasia and cartilage abnormalities with multiple synostoses and skeletal fractures. Birth Defects Orig Artic Ser 11:397-401.
5. Arlt W, Walker EA, Draper N, Ivison HE, Ride JP, Hammer F, Chalder SM, Borucka-Mankiewicz M, Hauffa BP, Malunowicz EM, et al. (2004) Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 363:2128-2135.
6. Black SD, French JS, Williams CH Jr, and Coon MJ (1979) Role of a hydrophobic polypeptide in the N-terminal region of NADPH-cytochrome P-450 reductase in complex formation with P-450LM. Biochem Biophys Res Commun 91:1528-1535.
7. Burke MD, Thompson S, Weaver RJ, Wolf CR, and Mayer RT (1994) Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol 48:923-936.
8. De Lano WL (2002) The PyMOL Molecular Graphics System, DeLano Scientific, Palo Alto, CA.
9. Dhir V, Ivison HE, Krone N, Shackleton CH, Doherty AJ, Stewart PM, and Arlt W (2007) Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Mol Endocrinol 21:1958-1968.
10. Duarte MP, Palma BB, Gilep AA, Laires A, Oliveira JS, Usanov SA, Rueff J, and Kranendonk M (2005a) The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450 mediated biotransformation. Mutagenesis 20:93-100.
11. Duarte MP, Palma BB, Laires A, Oliveira JS, Rueff J, and Kranendonk M (2005b) Escherichia coli BTC, a human cytochrome P450 competent tester strain with a high sensitivity towards alkylating agents: involvement of alkyltransferases in the repair of DNA damage induced by aromatic amines. Mutagenesis 20:199-208.
12. Fisher CW, Caudle DL, Martin-Wixtrom C, Quattrochi LC, Tukey RH, Waterman MR, and Estabrook RW (1992) High-level expression of functional human cytochrome P450 1A2 in Escherichia coli. FASEB J 6:759-764.
13. Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, Mendonça BB, Fujieda K, and Miller WL (2004) Mutant P450 oxidoreductase causes disordered steroido-genesis with and without Antley-Bixler syndrome. Nat Genet 36:228-230.
14. Fukami M, Horikawa R, Nagai T, Tanaka T, Naiki Y, Sato N, Okuyama T, Nakai H, Soneda S, Tachibana K, et al. (2005) Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J Clin Endocrinol Metab 90:414-426.
15. Gomes AM, Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M, and Zanger UM (2009) Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 10:579-599.
16. Hamdane D, Xia C, Im SC, Zhang H, Kim JJ, and Waskell L (2009) Structure and function of an NADPH-cytochrome P450 oxidoreductase in an open conformation capable of reducing cytochrome P450. J Biol Chem 284:11374-11384.
17. Hart SN, Li Y, Nakamoto K, Wesselman C, and Zhong XB (2007) Novel SNPs in cytochrome P450 oxidoreductase. Drug Metab Pharmacokinet 22:322-326.
18. Hart SN, Wang S, Nakamoto K, Wesselman C, Li Y, and Zhong XB (2008) Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics 18:11-24.
19. Hlavica P, Schulze J, and Lewis DF (2003) Functional interaction of cytochrome P450 with its redox partners: a critical assessment and update of the topology of predicted contact regions. J Inorg Biochem 96:279-297.
20. Homma K, Hasegawa T, Nagai T, Adachi M, Horikawa R, Fujiwara I, Tajima T, Takeda R, Fukami M, and Ogata T (2006) Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. J Clin Endocrinol Metab 91:2643-2649.
21. Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, Jabs EW, Van Vliet G, Sack J, Flück CE, et al. (2005) Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 76:729-749.
22. Huber WJ 3rd, Marohnic CC, Peters M, Alam J, Reed JR, Masters BS, and Backes WL (2009) Measurement of membrane-bound human heme oxygenase-1 activity using a chemically defined assay system. Drug Metab Dispos 37:857-864.
23. Hustad S, McKinley MC, McNulty H, Schneede J, Strain JJ, Scott JM, and Ueland PM (2002) Riboflavin, flavin mononucleotide, and flavin adenine dinucleotide in human plasma and erythrocytes at baseline and after low-dose riboflavin supplementation. Clin Chem 48:1571-1577.
24. Kmoch S, Zeman J, Hrebícek M, Ryba L, Kristensen MJ, and Gregersen N (1995) Riboflavin-responsive epilepsy in a patient with SER209 variant form of short-chain acyl-CoA dehydrogenase. J Inherit Metab Dis 18:227-229.
25. Kranendonk M, Carreira F, Theisen P, Laires A, Fisher CW, Rueff J, Estabrook RW, and Vermeulen NP (1999) Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies. Mutat Res 441:73-83.
26. Kranendonk M, Marohnic CC, Panda SP, Duarte MP, Oliveira JS, Masters BS, and Rueff J (2008) Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. Arch Biochem Biophys 475:93-99.
27. Kranendonk M, Mesquita P, Laires A, Vermeulen NP, and Rueff J (1998) Expression of human cytochrome P450 1A2 in Escherichia coli: a system for biotransformation and genotoxicity studies of chemical carcinogens. Mutagenesis 13:263-269.
28. Lakowicz JR (2006) Principles of Fluorescence Spectroscopy. Springer, New York. Marohnic CC, Panda SP, Martásek P, and Masters BS (2006) Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase. J Biol Chem 281:35975-35982.
29. Miller WL (2004) P450 oxidoreductase deficiency: a new disorder of steroidogenesis with multiple clinical manifestations. Trends Endocrinol Metab 15:311-315.
30. Nishino H and Ishibashi T (2000) Evidence for requirement of NADPH-cytochrome P450 oxidoreductase in the microsomal NADPH-sterol Delta7-reductase system. Arch Biochem Biophys 374:293-298.
31. Ono T and Bloch K (1975) Solubilization and partial characterization of rat liver squalene epoxidase. J Biol Chem 250:1571-1579.
32. Powers HJ (2003) Riboflavin (vitamin B-2) and health. Am J Clin Nutr 77:1352-1360.
33. Schacter BA, Nelson EB, Marver HS, and Masters BS (1972) Immunochemical evidence for an association of heme oxygenase with the microsomal electron transport system. J Biol Chem 247:3601-3607.
34. Seshagiri PB and Adiga PR (1987) Pregnancy suppression in the bonnet monkey by active immunisation with chicken riboflavin carrier protein. J Reprod Immunol 12:93-107.
35. Shen AL, Porter TD, Wilson TE, and Kasper CB (1989) Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis. J Biol Chem 264:7584-7589.
36. Vermilion JL and Coon MJ (1978) Identification of the high and low potential flavins of liver microsomal NADPH-cytochrome P-450 reductase. J Biol Chem 253:8812-8819.
37. Wang M, Roberts DL, Paschke R, Shea TM, Masters BS, and Kim JJ (1997) Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc Natl Acad Sci U S A 94:8411-8416.
38. Wang SL, Han JF, He XY, Wang XR, and Hong JY (2007) Genetic variation of human cytochrome P450 reductase as a potential biomarker for mitomycin C-induced cytotoxicity. Drug Metab Dispos 35:176-179.
39. Zhao Q, Modi S, Smith G, Paine M, McDonagh PD, Wolf CR, Tew D, Lian LY, Roberts GC, and Driessen HP (1999) Crystal structure of the FMN-binding domain of human cytochrome P450 reductase at 1.93 A resolution. Protein Sci 8:298-306.